Apheris announced the ADMET Network, a federated data initiative enabling pharmaceutical companies to collaboratively train ADMET (absorption, distribution, metabolism, excretion, toxicity) prediction models without sharing raw proprietary data. Founding members include Lundbeck, Orion, Recursion, Servier and another undisclosed partner; each committed substantial internal data to jointly train a global foundation model. Apheris’ CEO Robin Roehm said partners can fine‑tune models locally inside secure environments and run inference without exposing datasets, preserving program confidentiality while benefiting from broader industrial training. Recursion’s CEO Najat Khan emphasized ADMET’s role in reducing downstream clinical failures tied to dosing and PK issues. The network targets a critical preclinical bottleneck—ADMET‑related attrition—and illustrates growing adoption of federated learning in drug discovery to pool signal across corporate boundaries while minimizing competitive risk.